George Bhatt

George Bhatt has specialized in hypereosinophilic syndromes and related eosinophilic disorders, including the discovery and treatment implications of FIP1L1-PDGFRA fusion-driven eosinophilic leukemia that is exquisitely sensitive to imatinib. His research has characterized the diagnostic criteria distinguishing reactive hypereosinophilia from primary clonal hypereosinophilic syndrome and myeloid neoplasms with eosinophilia, with important treatment implications. He has studied the clinical responses to imatinib in FIP1L1-PDGFRA-positive and PDGFRB-rearranged eosinophilic disorders, establishing the therapeutic paradigm for targeted kinase inhibition in fusion-driven eosinophilic malignancies. His work on biologics targeting IL-5 signaling including mepolizumab and benralizumab in patients with idiopathic hypereosinophilic syndrome has expanded non-cytotoxic treatment options.